1. Scrip
  2. >>Digital Technologies
  3. >>AI

Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study

 
• By Alaric DeArment

The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.

• Source: Shutterstock

Results from Recursion Pharmaceuticals, Inc.’s Phase II SYCAMORE study of REC-994 in symptomatic cerebral cavernous malformation (CCM) drew uncertainty despite meeting the trial’s safety and tolerability primary endpoint, as the study showed signals of efficacy, but in a disease where there is a lack of clarity on what constitutes success.

Salt Lake City, UT-based Recursion announced the SYCAMORE results on 3 September, saying that the drug demonstrated “encouraging trends” in magnetic resonance imaging (MRI)-based exploratory efficacy measures at the highest dose of 400mg

Key Takeaways

  • Recursion is the first to produce Phase II results for a drug in symptomatic cerebral cavernous malformation, with SYCAMORE hitting its safety primary endpoint.

  • In the study, REC-994 showed signals of efficacy on MRI-based measures, but the bar for success in the disease remains unclear

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

More from Digital Technologies

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By Vibha Ravi

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 
• By Alaric DeArment

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.